Stock SGMT SAGIMET BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

Real-time Estimate Cboe BZX
Other stock markets
 12:32:16 2024-07-11 pm EDT 		5-day change 1st Jan Change
3.325 USD +6.23% Intraday chart for Sagimet Biosciences Inc. +9.82% -42.25%
Jul. 01 Goldman Sachs Downgrades Sagimet Biosciences to Neutral From Buy, Cuts Price Target to $6 From $23 MT
Jul. 01 Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell Small Cap Comp Value Index CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial
MT
Exchange-Traded Funds Edge Up, Equity Futures Mixed Pre-Bell Thursday as Investors Await Fresh Data
MT
Sagimet Biosciences Inc. Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
CI
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sagimet Biosciences Inc. Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
CI
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sagimet's shares hit new high as fatty liver disease drug shows promise in study
RE
Sagimet's fatty liver disease drug shows promise in trial
RE
Sagimet Biosciences Announces Positive Topline Results from Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Nash
CI
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
CI
Earnings Flash (SGMT) SAGIMET BIOSCIENCES Reports Q3 Revenue $2.0M
MT
Sagimet Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Sagimet Biosciences Inc. Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
CI
Sagimet Biosciences Q2 Loss Narrows
MT
Sagimet Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Sagimet Biosciences Says IPO Underwriters Partially Exercise Overallotment Option
MT
Sagimet Biosciences Inc. has completed an IPO in the amount of $85 million.
CI
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGMT Stock
  4. News Sagimet Biosciences Inc.
  5. Highlights